{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:ucenprubart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:devextinetug [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:murlentamab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03193190: Phase 1/Phase 2 Interventional Active, not recruiting Pancreatic Adenocarcinoma
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01899599: Phase 2 Interventional Completed Ovarian Epithelial Cancer Recurrent
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02979899: Phase 3 Interventional Completed Advanced Angiosarcoma
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:futermestotug [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04397562: Phase 3 Interventional Completed COVID-19
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00117936: Phase 2 Interventional Unknown status Coronary Disease
(2020)
Source URL:
Class:
PROTEIN